Biotechnology Industry - Publications - Faculty & Research - Harvard Business School

Filter Results: (402)

Filter Results: (402)

Show Results For

← Page 6 of 402 Results →

Sort by

Are you looking for?

→Search All HBS Web

October 2012 (Revised March 2022)
Case

Kleiner-Perkins and Genentech: When Venture Capital Met Science

By: Felda Hardymon and Tom Nicholas

Genentech is a rare success story in the biotechnology industry. Hundreds of billions of dollars of venture capital have been invested without the expected transformational effects. Established in 1976, Genentech was to develop the new science of recombinant DNA into... View Details

Keywords: Innovation ＆ Entrepreneurship; Venture Capital; Innovation and Invention; Entrepreneurship; Information Technology; Science; Biotechnology Industry; United States

November 2008 (Revised July 2009)
Background Note

A Managerial Perspective on Clinical Trials

By: Arthur A. Daemmrich

This note describes the history and regulation of clinical trials, managerial challenges related to pharmaceutical product testing, and current debates regarding prescription drug safety. Since clinical testing takes between five and seven years, and consumes up to 70... View Details

Keywords: Governing Rules, Regulations, and Reforms; Health Testing and Trials; Product Development; Safety; Biotechnology Industry; Biotechnology Industry

April 1993 (Revised May 1994)
Case

Genzyme Corporation: Strategic Challenges with Ceredase

Genzyme Corp., one of the largest biotechnology companies, has succeeded in developing, manufacturing, and commercializing its first therapeutic, a treatment for a rare genetic disease. Analysis of the case requires students to identify and understand how Genzyme has... View Details

Keywords: Risk Management; Risk and Uncertainty; Corporate Strategy; Technology; Health; Product Development; Biotechnology Industry; Biotechnology Industry; United States

January 2011 (Revised January 2012)
Supplement

The Case of the Unidentified Healthcare Companies2010 (CW)

By: Richard M.J. Bohmer, Ethan S Bernstein, Margarita Krivitski and Srinidhi Reddy

This case presents financial statements and selected rations for 14 unidentified healthcare organizations and asks that each set of financial information be matched with one of the following healthcare companies: a biotechnology firm, a community nursing company, a... View Details

Keywords: Financial Statements; Financial Management; Health Care and Treatment; Biotechnology Industry; Biotechnology Industry

February 2006 (Revised August 2006)
Case

deCODE Genetics: Hunting for Genes to Develop Drugs

By: Debora L. Spar

In 1996, Kari Stefansson launched a new kind of biotechnology company and a whole new way of attacking diseases. Based in Iceland, his firm, deCODE Genetics, plans to identify the individual genetic markers that lead to society's most prevalent diseases. To do so, it... View Details

Keywords: Information; Innovation Strategy; Genetics; Ethics; Health Disorders; Biotechnology Industry; Iceland

February 2010
Case

Amyris Biotechnologies: Commercializing Biofuel

By: Gary P. Pisano and Alison Berkley Wagonfeld

In 2009, Amyris Biotechnologies was building a plant in Brazil that used synthetic biology to convert sugarcane into both renewable fuels and renewable chemicals. The Amyris' marketing team was investigating the commercial interest for both types of products, while the... View Details

Keywords: Renewable Energy; Chemicals; Risk Management; Product Marketing; Product Development; Production; Environmental Sustainability; Commercialization; Biotechnology Industry; Brazil

January 2011 (Revised January 2012)
Case

The Case of the Unidentified Healthcare Companies2010

By: Richard Bohmer, Ethan Bernstein, Margarita Krivitski and Srinidhi Reddy

This case presents financial statements and selected ratios for 14 unidentified healthcare organizations and asks that each set of financial information be matched with one of the following healthcare companies: a biotechnology firm, a community nursing company, a... View Details

Keywords: Financial Reporting; Financial Statements; Health Care and Treatment; Health Industry

November 2003 (Revised December 2003)
Case

Proteome Systems Limited: The First Five Years

A Sydney-based biotechnology company is moving from the development of proteomics technology to the commercialization of its first instruments in the worldwide proteomics market. The case study highlights the range of activities engaged in by the 120-person company,... View Details

Keywords: Organizational Change and Adaptation; Information Technology; Commercialization; Entrepreneurship; Biotechnology Industry; Sydney

Find at Harvard

May 2007 (Revised September 2008)
Case

Biocon Limited

By: Krishna G. Palepu and Ananth Chepuri

Biocon Limited was facing significant pricing pressure in their cash cow business, that primarily consisted of manufacturing Active Pharmaceutical Ingredients (APIs). To combat this commoditization, Biocon's leadership had chosen an innovation-led strategy. This new... View Details

Keywords: Globalized Firms and Management; Innovation and Management; Leading Change; Growth and Development Strategy; Risk Management; Organizational Change and Adaptation; Biotechnology Industry; India

Article

Network Effects in the Governance of Strategic Alliances

We argue that the stock of prior alliances between participants in the biotechnology sector forms a network that serves as a governance mechanism in interfirm transactions. To test how this network substitutes for other governance mechanisms, we examine how equity... View Details

Keywords: Network Effects; Governance; Strategy; Alliances; Stocks; Market Transactions; Equity; Mortgages; Biotechnology Industry

Find at Harvard

2010
Working Paper

Venture Capital Investment in the Clean Energy Sector

By: Shikhar Ghosh and Ramana Nanda

We examine the extent to which venture capital is adequately positioned for the rapid commercialization of clean energy technologies in the United States. While there are several startups in clean energy that are well-suited to the traditional venture capital... View Details

Keywords: Business Startups; Energy Generation; Venture Capital; Investment; Governing Rules, Regulations, and Reforms; Technological Innovation; Competition; Energy Industry; Energy Industry; United States

June 2006 (Revised April 2007)
Case

BioScale

By: H. Kent Bowen and Bradley R. Staats

In 2004, Mark Lundstrom must decide on a funding method and strategic approach for BioScale, a biotechnology company that he founded. BioScale has developed a microchip-based bioanalytical platform that can be used to detect very small concentrations of cells, viruses,... View Details

Keywords: Entrepreneurship; Science-Based Business; Capital; Financing and Loans; Partners and Partnerships; Biotechnology Industry

June 2006 (Revised January 2012)
Case

Teena Lerner: Dividing the Pie at Rx Capital (A)

By: Boris Groysberg, Victoria Winston and Robin Abrahams

Teena Lerner started her own hedge fund firm in 2001 after nearly 20 years as a star biotechnology analyst and hedge fund manager. After the start-up phase, her firm became highly profitable. In 2004, however, one of her four analysts lost a lot of money for the firm.... View Details

Keywords: Managerial Roles; Investment Funds; Performance; Business Startups; Compensation and Benefits; Corporate Finance; Financial Services Industry

July 2016
Case

Product Portfolio Management at Genentech

By: Kevin Schulman and Jamie Gresh

Genentech, long the darling of the biotechnology industry, was acquired by Swiss pharmaceutical company Roche in 2009. The combined company retains the name Genentech in the US, but must now move to achieve the promises made at the time of this merger—to build from... View Details

Keywords: Portfolio Management; Drug Development; Postmerger Integration; Marketing Strategy; Mergers and Acquisitions; Integration; Biotechnology Industry; Biotechnology Industry; United States

February 2000 (Revised October 2000)
Case

Kendle International Inc.

By: Dwight B. Crane, Paul W. Marshall and Indra Reinbergs

Candace Kendle and Christopher Bergen, the CEO and COO of Kendle International, Inc., are reviewing ways to finance the growth of their privately-owned company. Kendle is a contract research organization that conducts clinical drug trials for pharmaceutical and... View Details

Keywords: Acquisition; Financing and Loans; Venture Capital; Stock Options; Banks and Banking; Debt Securities; International Finance; Financial Strategy; Management Skills; Private Ownership; Initial Public Offering; Biotechnology Industry; Biotechnology Industry

December 1999 (Revised August 2001)
Case

Millennium Pharmaceuticals, Inc. (A)

By: Stefan H. Thomke and Ashok Nimgade

Focuses on Millennium's strategy to grow and revolutionize drug development through the use of new technologies such as genomics. Describes how Millennium Pharmaceuticals--a fast-growing biotechnology firm in Cambridge, MA--has used strategic alliances to finance the... View Details

Keywords: Cost Management; Financing and Loans; Medical Specialties; Retention; Growth and Development Strategy; Time Management; Product Development; Problems and Challenges; Alliances; Technology; Biotechnology Industry; Biotechnology Industry; Cambridge

January 2020
Case

Celata Bioinnovations

By: John R. Wells and Benjamin Weinstock

In December 2019, Jon Hu (HBS ‘19) and Dr. Samantha Dale Strasser, co-founders of Celata Bioinnovations, were raising $1 million to launch their company. They had founded Celata less than six months earlier with the aim of redefining the drug discovery process.... View Details

April 1993 (Revised October 1995)
Case

ALZA and Bio-Electro Systems (A): Technological and Financial Innovation

By: Josh Lerner and Peter Tufano

To develop the next generation of risky products, ALZA, a mature and profitable biotechnology firm specializing in drug delivery systems, must raise $40 million. Organizational constraints and competitive concerns demand that the work be done inside the firm. However,... View Details

Keywords: Risk and Uncertainty; Technological Innovation; Business Subsidiaries; Decision Choices and Conditions; Corporate Finance; Biotechnology Industry; Biotechnology Industry

December 2006 (Revised October 2007)
Case

Monsanto: Realizing Biotech Value in Brazil

By: David E. Bell and Mary L. Shelman

In 2003, Monsanto's patented "Roundup Ready" technology was used illegally on 70-80% of the soybean area in southern Brazil. Under pressure from U.S. soybean growers, who were paying to license the technology, the firm implemented an innovative delivery-based... View Details

Keywords: Plant-Based Agribusiness; Patents; Lawfulness; Emerging Markets; Product Development; Agriculture and Agribusiness Industry; Agriculture and Agribusiness Industry; Brazil

May 2009 (Revised August 2013)
Case

The DiagnoFirst Opportunity

By: Robert C. Pozen and Rukmini Balu

John Mason, a principle at Oldwell Partners, was facing a decision of whether or not to invest in DiagnoFirst, a molecular diagnostics firm. DiagnoFirst's key product was a genetic test that identified a subset of prostate cancer patients with a high risk of clinical... View Details

Keywords: Genetic Engineering; Genetically Modified; Genomics; Venture Capital; Patents; Genetics; Decision Choices and Conditions; Laws and Statutes; Investment; Science-Based Business; Biotechnology Industry

←
6
7
…
20
21
→